HIV/AIDS

$600B+
Global Research Spending Since 1981
43
Years Since Discovery
39M
People Living with HIV
Limited
Functional Cure Cases

Four Decades of Prevention Progress, Limited Cure

HIV was identified in 1981. Forty-three years later, 39 million people live with HIV globally. Over $600 billion has been spent on research. The virus remains incurable for the vast majority of infected individuals. Death from HIV is now rare in developed countries. This is a treatment success story. It is not a cure story.

Antiretroviral therapy turned HIV from a death sentence into a manageable chronic condition. A person diagnosed with HIV today, if treated, can expect a normal lifespan. Prevention through PrEP has reduced new infections. Progress on these fronts is real and measurable. A scalable cure remains elusive.

First AIDS Case Documented 1981
First Antiretroviral Drug (AZT) 1987
HAART Era Begins 1996
Berlin Patient Functional Cure 2007
Functional Cure Cases (Global) 5

The Promise vs. Reality Pattern

1981
Discovery: First cases identified. Unknown pathogen. Death within months to years.
1987
Promise: AZT approved. First antiretroviral. Hope for treatment. Still terminal disease.
1996
Transformation: HAART (triple therapy) demonstrated. Viral loads became undetectable. Death rates plummeted. A chronic disease, not a death sentence.
2007
Case Study: Berlin Patient: Timothy Ray Brown. Stem cell transplant from CCR5-delta32 donor. Virus undetectable. Functional cure for one patient.
2019
Replication Attempt: London Patient (Adam Castillejo): Similar approach. Virus undetectable. Two documented cases in two decades.
2020s
Current Status: mRNA vaccine trials underway. Broadly neutralizing antibody research ongoing. No scalable cure. Standard treatment controls virus indefinitely.

Current Research Status

HIV research has shifted focus from treatment to cure and prevention. ART is standard. The question now is whether a sterilizing cure (eradication of latent virus) can be achieved. The answer remains unknown.

Active Clinical Trials 150+
mRNA Vaccine Candidates 3 in Phase 2
Annual Global Spending $20B
People on Suppressive ART 28M
Functional Cure Cases (Documented) 5

What This Means: Treatment works. Prevention works. Cure remains theoretical for the general population. Functional cures via stem cell transplant exist but are not scalable--they require a donor match (CCR5-delta32) that is rare in most populations and is only used in patients with concurrent blood cancer. The goal is a cure accessible to millions, not a handful of exceptional cases.

Sources & Methodology

Data compiled from NIH, WHO, peer-reviewed sources, and published clinical trial data.

Primary Sources

  • National Institutes of Health -- HIV Research Funding (RePORT Database)
  • UNAIDS -- Global HIV Statistics (2023--2024)
  • CDC -- HIV Treatment and Viral Suppression (NHBS and NHAS data)
  • ClinicalTrials.gov -- HIV Vaccine and Cure Research Trials (150+ active)
  • Nature Medicine -- HIV Functional Cure Cases and Mechanisms (2019--2023)
  • The Lancet HIV -- Current Antiretroviral Treatment Outcomes (2023)
  • NIH National Center for Biotechnology Information -- mRNA Vaccine Development for HIV